Traditional endpoints, design and analysis methods in Oncology may not be appropriate for Immuno-Oncology. Novel endpoints based on the wealth of data collected over the recent years will be explored as alternatives. Their relationship to long-term survival will be discussed. Additionally, the issues related to event-based designs owing to non-proportional hazards will be illustrated using examples. Some possible solutions to overcome these issues will be discussed.